Ching-Sheng Hsu1,2, Shih-Jer Hsu3,4, Hung-Chia Chen5, Chen-Hua Liu3,6, Jenher Jeng7, Chun-Jen Liu3,6, Pei-Jer Chen3,6,8, Ding-Shinn Chen3,6, Jia-Horng Kao9,10,11,12. 1. Division of Gastroenterology, Department of Internal Medicine, Buddhist Tzu Chi General Hospital, Taipei, Taiwan. 2. School of Medicine, Tzu Chi University, Hualien, Taiwan. 3. Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, National Taiwan University Hospital, Taipei, Taiwan. 4. Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Yun-Lin, Taiwan. 5. Division of Personalized Nutrition and Medicine, National Center for Toxicological Research, FDA, Jefferson, USA. 6. Department of Internal Medicine, National Taiwan University College of Medicine, National Taiwan University Hospital, Taipei, Taiwan. 7. Center of Mathematical Modeling and Scientific Computing, National Chiao Tung University, Hsinchu, Taiwan. 8. Hepatitis Research Center, National Taiwan University College of Medicine, National Taiwan University Hospital, Taipei, Taiwan. 9. Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, National Taiwan University Hospital, Taipei, Taiwan. kaojh@ntu.edu.tw. 10. Department of Internal Medicine, National Taiwan University College of Medicine, National Taiwan University Hospital, Taipei, Taiwan. kaojh@ntu.edu.tw. 11. Department of Medical Research, National Taiwan University College of Medicine, National Taiwan University Hospital, Taipei, Taiwan. kaojh@ntu.edu.tw. 12. Hepatitis Research Center, National Taiwan University College of Medicine, National Taiwan University Hospital, Taipei, Taiwan. kaojh@ntu.edu.tw.
Abstract
PURPOSE: IL28B genotypes have a strong impact on treatment outcomes of chronic hepatitis C (CHC) and on-treatment viral kinetics. Since metabolic regulation and interferon response are highly integrated, metabolic profiles may play an important role in the link between IL28B genotypes and hepatitis C virus (HCV) infection. Thus, the association of IL28B rs8099917 genotypes with metabolic profiles and the impact of metabolic profiles on hepatitis C viral kinetic parameters were examined. METHODS: A case-control analysis including 278 CHC patients and 280 subjects without chronic HCV infection was performed. The associations of IL28B rs8099917 genotype with pretreatment metabolic profiles and early viral kinetic parameters were evaluated. RESULTS: Compared to HCV genotype 1 patients, the differences in metabolic profiles were more significant in genotype 2 patients. HCV genotype 2 patients with TT genotype had higher serum total cholesterol and high density lipoprotein (HDL) levels than those with GT genotype, and the differences remained significant when adjusted for age, sex, and body mass index (p = 0.005 for total cholesterol; p = 0.006 for HDL). In addition, patients with higher serum TG, higher fasting blood glucose, and lower HDL had a lower viral clearance rate. CONCLUSIONS: IL28B genotypes may affect lipid profiles of CHC patients, especially in HCV-genotype 2 patients. Patients with higher serum fasting blood glucose, triglyceride, and lower HDL have a lower viral clearance rate during pegylated interferon plus ribavirin therapy.
PURPOSE:IL28B genotypes have a strong impact on treatment outcomes of chronic hepatitis C (CHC) and on-treatment viral kinetics. Since metabolic regulation and interferon response are highly integrated, metabolic profiles may play an important role in the link between IL28B genotypes and hepatitis C virus (HCV) infection. Thus, the association of IL28Brs8099917 genotypes with metabolic profiles and the impact of metabolic profiles on hepatitis C viral kinetic parameters were examined. METHODS: A case-control analysis including 278 CHCpatients and 280 subjects without chronic HCV infection was performed. The associations of IL28Brs8099917 genotype with pretreatment metabolic profiles and early viral kinetic parameters were evaluated. RESULTS: Compared to HCV genotype 1 patients, the differences in metabolic profiles were more significant in genotype 2 patients. HCV genotype 2 patients with TT genotype had higher serum total cholesterol and high density lipoprotein (HDL) levels than those with GT genotype, and the differences remained significant when adjusted for age, sex, and body mass index (p = 0.005 for total cholesterol; p = 0.006 for HDL). In addition, patients with higher serum TG, higher fasting blood glucose, and lower HDL had a lower viral clearance rate. CONCLUSIONS:IL28B genotypes may affect lipid profiles of CHCpatients, especially in HCV-genotype 2 patients. Patients with higher serum fasting blood glucose, triglyceride, and lower HDL have a lower viral clearance rate during pegylated interferon plus ribavirin therapy.
Authors: Stephen A Harrison; Lorenzo Rossaro; Ke-Qin Hu; Keyur Patel; Hans Tillmann; Sandeep Dhaliwal; Dawn M Torres; Kenneth Koury; Venkata S Goteti; Stephanie Noviello; Clifford A Brass; Janice K Albrecht; John G McHutchison; Mark S Sulkowski Journal: Hepatology Date: 2010-09 Impact factor: 17.425
Authors: Daniele Prati; Mitchell L Shiffman; Moisés Diago; Edward Gane; K Rajender Reddy; Paul Pockros; Patrizia Farci; Christopher B O'Brien; Pilar Lardelli; Steven Blotner; Stefan Zeuzem Journal: J Hepatol Date: 2006-01-25 Impact factor: 25.083
Authors: M Yoneda; S Saito; T Ikeda; K Fujita; H Mawatari; H Kirikoshi; M Inamori; Y Nozaki; T Akiyama; H Takahashi; Y Abe; K Kubota; T Iwasaki; Y Terauchi; S Togo; A Nakajima Journal: J Viral Hepat Date: 2007-09 Impact factor: 3.728
Authors: David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington Journal: Nature Date: 2009-10-08 Impact factor: 49.962